ARDX
Price
$3.98
Change
+$0.01 (+0.25%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
947.45M
68 days until earnings call
RNAC
Price
$9.12
Change
-$0.03 (-0.33%)
Updated
May 23, 04:59 PM (EDT)
Capitalization
237.35M
Interact to see
Advertisement

ARDX vs RNAC

Header iconARDX vs RNAC Comparison
Open Charts ARDX vs RNACBanner chart's image
Ardelyx
Price$3.98
Change+$0.01 (+0.25%)
Volume$26.84K
Capitalization947.45M
Cartesian Therapeutics
Price$9.12
Change-$0.03 (-0.33%)
Volume$2.74K
Capitalization237.35M
ARDX vs RNAC Comparison Chart
Loading...
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARDX vs. RNAC commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Hold and RNAC is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (ARDX: $3.96 vs. RNAC: $9.15)
Brand notoriety: ARDX and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 44% vs. RNAC: 58%
Market capitalization -- ARDX: $947.45M vs. RNAC: $237.35M
ARDX [@Biotechnology] is valued at $947.45M. RNAC’s [@Biotechnology] market capitalization is $237.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, ARDX is a better buy in the long-term than RNAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 5 TA indicator(s) are bullish while RNAC’s TA Score has 3 bullish TA indicator(s).

  • ARDX’s TA Score: 5 bullish, 5 bearish.
  • RNAC’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both ARDX and RNAC are a good buy in the short-term.

Price Growth

ARDX (@Biotechnology) experienced а +17.16% price change this week, while RNAC (@Biotechnology) price change was -12.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.05%. For the same industry, the average monthly price growth was +3.15%, and the average quarterly price growth was -3.91%.

Reported Earning Dates

ARDX is expected to report earnings on Jul 31, 2025.

RNAC is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (+1.05% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARDX($947M) has a higher market cap than RNAC($237M). ARDX YTD gains are higher at: -21.893 vs. RNAC (-48.939). ARDX has higher annual earnings (EBITDA): -28.23M vs. RNAC (-83.55M). ARDX has more cash in the bank: 214M vs. RNAC (180M). RNAC has less debt than ARDX: RNAC (14.1M) vs ARDX (155M). ARDX has higher revenues than RNAC: ARDX (362M) vs RNAC (34.2M).
ARDXRNACARDX / RNAC
Capitalization947M237M400%
EBITDA-28.23M-83.55M34%
Gain YTD-21.893-48.93945%
P/E RatioN/A1.72-
Revenue362M34.2M1,058%
Total Cash214M180M119%
Total Debt155M14.1M1,099%
FUNDAMENTALS RATINGS
ARDX vs RNAC: Fundamental Ratings
ARDX
RNAC
OUTLOOK RATING
1..100
6156
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
8893
P/E GROWTH RATING
1..100
4360
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARDX's Valuation (98) in the Biotechnology industry is in the same range as RNAC (99). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

ARDX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RNAC (100). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

ARDX's SMR Rating (94) in the Biotechnology industry is in the same range as RNAC (99). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

ARDX's Price Growth Rating (88) in the Biotechnology industry is in the same range as RNAC (93). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

ARDX's P/E Growth Rating (43) in the Biotechnology industry is in the same range as RNAC (60). This means that ARDX’s stock grew similarly to RNAC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXRNAC
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 22 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICERX43.220.04
+0.09%
NYLI Epoch International Chc SIMPLE Cl
LOGBX36.14N/A
N/A
Scharf Multi-Asset Opportunity Retail
PEEAX14.12N/A
N/A
PGIM Jennison Mid-Cap Growth A
PQSCX23.65N/A
N/A
Virtus KAR Small-Cap Value C
SLMCX116.21N/A
N/A
Columbia Seligman Tech & Info A

ARDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARDX has been loosely correlated with VCYT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ARDX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARDX
1D Price
Change %
ARDX100%
-0.75%
VCYT - ARDX
45%
Loosely correlated
N/A
HRTX - ARDX
37%
Loosely correlated
-0.53%
PCVX - ARDX
35%
Loosely correlated
-0.06%
RNAC - ARDX
33%
Poorly correlated
-1.45%
CLRB - ARDX
31%
Poorly correlated
N/A
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with SNPX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-1.45%
SNPX - RNAC
91%
Closely correlated
-3.86%
ALLR - RNAC
86%
Closely correlated
-1.39%
NRXP - RNAC
86%
Closely correlated
+2.28%
PALI - RNAC
81%
Closely correlated
N/A
VRDN - RNAC
41%
Loosely correlated
+0.07%
More